The latest news from academia, regulators
research labs and other things of interest
Posted: May 11, 2010
Iris BioTechnologies Awarded New Patent For Its Nano-Biochip
(Nanowerk News) Iris BioTechnologies Inc., a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, and recipient of the Frost and Sullivan 2008 Technology Innovation Award in Pharmacogenomics, today announced two new Canadian patents. This brings the company's total patent portfolio to four Canadian patents, four U.S. patents, and numerous other patents in the European Union, Asia, Australia and New Zealand.
"This is an exciting time for Iris BioTechnologies as we continue building our valuable portfolio of intellectual property not only in the United States but around the world," said CEO Simon Chin. "Over the past year, we have designed and built a patent-protected, advanced chip-making system which positions Iris in the forefront of personalized medicine. These patents protect our technologies improving our outlook for product, service, and licensing revenue streams going forward."
One of these two patents protects Iris's Nano-Biochip™ enabling the use of probes with superior binding affinity and specificity to be incorporated into the technology platform. The second patent on the company's BioWindows™ Informatics System enables a more effective diagnosis and targeted treatment for breast cancer, colon cancer, neurological disorders, heart disease, diabetes and gene-related metabolic problems. Data provided by the company's Nano-Biochip™, along with the patient's medical history, family medical history, life dynamic factors, and environmental exposures, are stored and analyzed by BioWindows™ to help clinicians choose the most personalized protocol for their patients.
According to PricewaterhouseCoopers LLP, the annual market for diagnostic tests and drugs tailored to individuals was expected to total $24 billion last year and grow 10 percent annually, reaching $42 billion by 2015.
About Iris BioTechnologies Inc.
Iris BioTechnologies Inc., located in Santa Clara, CA, is a life sciences company dedicated to creating a novel approach to monitor gene and protein activities in order to identify the ideal treatment solution for patients. By categorizing individuals according to their molecular signatures and personal profiles, the company accurately determines the optimal medical solution for each individual patient through a proprietary informatics system called BioWindows. The company's continually expanding database, in addition to their development of the BreastCancerChip™, ColonCancerChip™, ComprehensiveCancerChip™, NeuroChip™, CardioChip™, and MetabolicChip™ adds to their extensive product pipeline.